| BackgroundBreast cancer, which is a serious threat to women’s health, is one of the common malignant tumors. In recent years, because of the development of China’s economic, improvement of living standards and changes in eating habits, Chinese women breast diseases are increasing, particularly the rising incidence of breast cancer, those impact on women’s quality of life seriously. Therefore, breast cancer patients as a group cannot be ignored.The development and progression of breast cancer is closely related to the expression of hormone receptors and genes and is a complex process. Molecular biology studies have shown that certain molecular markers were related to the prognosis and treatment of breast cancer. Researching these indicators in breast cancer tissues will help us to determine the clinical treatment and prognosis of breast cancer patients.ObjectiveBy detecting the expression of hormone receptors and genes in primary invasive ductal carcinoma, exploring the correlation between these indicators and the clinical stage and tumor size, the researchers are trying to find out the effect of the development of breast cancer, which in order to screen out the valuable clinical indicators and provide the molecular biology basis for breast cancer prognosis, clinical therapy and immunotherapy.Methods101cases who are invasive ductal breast cancer with a complete clinical and pathological in Henan Province People’s Hospital from October2010to June2011were selected, and clinical data were collected and tissue wax block. Researchers detected the expression level of P53, C-erbB-2, ER, PR, CD44v6, E-cad, ki67, Topoisomerase II, and nm23in breast invasive ductal carcinoma by immunohistochemistry, and then combined with the clinical and pathological features-tumor size and clinical stage to analyze these indicators and patient prognosis. Using spss software, we researched relevant clinical indicators by the χ2test.Results1. The clinical features of101cases invasive ductal carcinoma:the age distribution was from28to85years old, median age was49years old. Among28-50years old,57cases (56.4%),51-85years old,44cases (43.6%). Clinical stage and tumor size was based on the2000China tumor pathology classification criteria. Its general situation was:clinical stage:Ⅰ period17people (16.8%); Ⅱ period61people (60.4%); Ⅲ period23people (22.8%). Tumor size distribution:T117people (16.8%); T271people (70.3%); T39people (8.9%). The relationship between age distribution and tumor size and clinical stage were not statistically significant (P>0.05).2. The positive expression rate of P53, nm23, ER, PR, CD44v6, E-cad, ki67, Topoisomerase Ⅱ in breast invasive ductal carcinoma was69.3%,40.6%,69.3%,61.4%,64.4%,71.3%,68.3%,45.5%. In addition, ER, CD44v6expression intensity was significantly correlated with tumor size (P<0.05), the correlation coefficient is0.382and0.483. C-erbB-2, ki67expression intensity was significantly correlated with clinical stage (P<0.05), the correlation coefficient is0.585and0.353. Other indicators were not show significantly associated with clinical pathology (P>0.05).Conclusions1. The relationship between age distribution and clinical stage and tumor size had no correlation.2. In invasive ductal carcinoma, ER and C-erbB-2respectively significantly associated with tumor size and clinical classification. CD44v6as an indicator for tumor cell adhesion and transfer was related to tumor size. Ki67, which was related to clinical stage, is an indicator to test tumor cell proliferation. |
PDF Full Text Request